抗肿瘤树突状细胞疫苗研究进展  

The Progress of Dendritic Cell-based Tumor Vaccinations

作　　者：雷健 王丽君 

机构地区：[1]东北制药集团股份有限公司,辽宁沈阳110027

出　　处：《中国药物评价》2013年第6期364-367,共4页Chinese Journal of Drug Evaluation

摘　　要：树突状细胞(DCs)是一类独特的抗原递呈细胞,具有活化T细胞并诱导抗原特异性毒性T淋巴细胞的能力。研究表明,DCs构成了一套启动并调节免疫应答的复杂系统,能够诱导免疫应答,调控免疫耐受。近年来,针对癌症患者的治疗方案迅速增加,负载肿瘤抗原的树突状细胞疫苗作为一种新兴的免疫治疗技术,也被应用于癌症患者的治疗。本研究拟对目前关于DCs的特点和功能,以及在癌症的免疫耐受机理等方面的研究结果进行综述,并讨论与展望DCs疫苗所存在的问题与发展方向。Dendritic cells （DCs） are unique specialized antigen-presenting cells capable of priming naive T cells and inducing anti- gen-specific cytotoxic T lymphocytes. There are increasing evidences that DCs constitute a complex system of cells that initiate and regu- late immune responses, and result to two opposite outcomes ： immunity or tolerance. In recent years, varieties of treatments for cancer pa- tients have increased rapidly, tumor antigen pulsed dendritic cell-based vaccination as a immune therapy is treated to cancer patients. This paper describes some of the characters and functions of DCs, the mechanism of tolerance in cancer, and discusses the problems and perspectives for dendritic cell vaccines for cancer patients.

关 键 词：树突状细胞 抗肿瘤疫苗 免疫治疗 免疫耐受 

分 类 号：R392[医药卫生—免疫学]